#United States #Oklahoma City #diagnostics #Lupus #Progentec

Progentec Diagnostics Revolutionizes Lupus Diagnostic Timeline

Progentec Diagnostics is making headlines with its groundbreaking findings presented at the LUPUS 2025 conference. This leader in advanced diagnostic solutions has demonstrated a significant advancement in the classification of systemic lupus erythematosus (SLE), more commonly known as lupus. Traditionally, patients navigating the diagnostic journey for lupus face an exhausting wait of five to seven years, filled with multiple doctor visits and varying opinions. However, Progentec's innovative virtual classification program, known as PROACTIVE™, has successfully slashed this timeline by an impressive 80%.

The study's findings, detailed in The Journal of Rheumatology, reveal that patients were able to receive a definitive classification in just over one year. Dr. Timothy Niewold, a leading rheumatologist involved in the study, emphasized the profound impact of this virtual model, stating, "This study showed that participants who ultimately met SLE classification criteria were identified in just over one year—compared to the traditional timeline typically required." This transformative approach is designed to enhance access to the care needed by those suffering from this chronic autoimmune disease.

Lupus, which can severely affect multiple organ systems, has long been recognized as a condition that complicates patients’ lives and disrupts their quality of life. Historically, the quest for a diagnosis has been prolonged and fraught with obstacles, leading to delayed treatments and detrimental health outcomes. Progentec’s study not only provides a roadmap for a more efficient classification process but also highlights the potential of digital health tools and biomarkers in modern medicine.

Participants in the study went through a fully digital process utilizing Progentec's online screening platform, Autoimmuneornot.com. With over 206,000 users to date, this connective tissue disease screening questionnaire identifies individuals who may exhibit signs of lupus. Those flagged during the screening were invited to participate in the PROACTIVE™ study.

This comprehensive and virtual diagnostic journey included:

• - Telehealth Consultations: Participants received consultations from primary care providers as well as rheumatology specialists.
• - At-Home Blood Testing: A mobile phlebotomy service facilitated lab tests for biomarkers associated with lupus.
• - Expert Review: The individuals’ medical records and lab results were meticulously reviewed by expert rheumatologists.
• - SLE Classification: Final classifications were determined based on well-established criteria from the ACR and EULAR/ACR guidelines.

Staggering results from the study indicated that 18% of participants were classified with SLE, while 46% were determined to have incomplete SLE, and 36% showed no indications of the disease. Dr. Eldon Jupe, the principle investigator, highlighted the accelerated timeline that this model could achieve in practical clinical settings, commenting, "The ability to inform their primary care physician that they have been potentially classified as a lupus patient is a major accomplishment."

This pioneering approach to lupus classification is greatly aided by funding from GSK and aligns with Progentec's ongoing mission to develop patient-centered, technology-enhanced solutions. The implications of this study are vast, suggesting that future research and application of these findings could lead to not only a faster and more accurate classification process but make it accessible to a broader patient base.

For those seeking more information on Progentec's advancements in lupus diagnostics, resources are available at Progentec's official website www.progentec.com.

By paving the way for faster classifications and facilitating earlier access to care, Progentec Diagnostics is solidifying its position as a trailblazer in the field of autoimmune disease management.